Overview

Residual Renal Function Preservation in Peritoneal Dialysis Patients

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
0
Participant gender:
All
Summary
Aldosterone blockade is useful in preserving residual renal function in patients on PD.The long term efficacy of dual blockade of the RAAS is better than monotherapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Xiangya Hospital of Central South University
Collaborator:
Baxter Healthcare Corporation
Treatments:
Losartan
Spironolactone
Criteria
Inclusion Criteria:

- Patients who having been on PD continuously for one month, urine volume>600 ml/d,
residual renal function>2ml/min/1.73m2, blood pressure>120/70mmHg, serum potassium
levels<5.5mmol/l, stable clinical condition.

Exclusion Criteria:

- Patients with infectious systemic disease, peritonitis during the preceding 1 month,
who had taken ACEI/ARBs in the 3 preceding months, spirolactone in the 2 preceding
weeks, intolerance to ACEI/ARBs, CHF, MI, malignant hypertension and stroke within the
preceding 6 months.